The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1201
January 31, 2005
View Complete Issue         Table of Contents 2019 
Azacitidine (Vidaza) for Myelodysplastic Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Azacitidine (Vidaza) for Myelodysplastic Syndrome
January 31, 2005 (Issue: 1201)
Azacitidine (Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly synthesized DNA and inhibits DNA...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Azacitidine (Vidaza) for Myelodysplastic Syndrome
Article code: 1201b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.